Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients

Jenna Rossoff; Ami B. Patel; Emily Muscat; Larry K. Kociolek; William J. Muller

doi:10.1002/pbc.28504

Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients

Jenna Rossoff^*, Ami B. Patel, Emily Muscat, Larry K. Kociolek, William J. Muller

^*Corresponding author for this work

Pediatrics

Research output: Contribution to journal › Letter › peer-review

16 Scopus citations

Original language	English (US)
Article number	e28504
Journal	Pediatric Blood and Cancer
Volume	67
Issue number	9
DOIs	https://doi.org/10.1002/pbc.28504
State	Published - Sep 1 2020

ASJC Scopus subject areas

Pediatrics, Perinatology, and Child Health
Hematology
Oncology

Access to Document

10.1002/pbc.28504

Cite this

@article{aa94569c30c848a98abf34f611490bd8,

title = "Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients",

author = "Jenna Rossoff and Patel, {Ami B.} and Emily Muscat and Kociolek, {Larry K.} and Muller, {William J.}",

note = "Funding Information: Jenna Rossoff, Ami B. Patel, and Emily Muscat declare that there is no conflict of interest or competing financial interest. Larry K. Kociolek received grant funding from Merck. William J. Muller is consulting for Seqirus, Inc. and received research funding for clinical trials from Abbott Laboratories, Ansun BioPharma, Astellas Pharma, AstraZeneca, Janssen Pharmaceutica, Karius, Melinta, Merck, Roche, and Tetraphase. ",

year = "2020",

month = sep,

day = "1",

doi = "10.1002/pbc.28504",

language = "English (US)",

volume = "67",

journal = "Medical and Pediatric Oncology",

issn = "1545-5009",

publisher = "Wiley-Liss Inc.",

number = "9",

}

TY - JOUR

T1 - Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients

AU - Rossoff, Jenna

AU - Patel, Ami B.

AU - Muscat, Emily

AU - Kociolek, Larry K.

AU - Muller, William J.

N1 - Funding Information: Jenna Rossoff, Ami B. Patel, and Emily Muscat declare that there is no conflict of interest or competing financial interest. Larry K. Kociolek received grant funding from Merck. William J. Muller is consulting for Seqirus, Inc. and received research funding for clinical trials from Abbott Laboratories, Ansun BioPharma, Astellas Pharma, AstraZeneca, Janssen Pharmaceutica, Karius, Melinta, Merck, Roche, and Tetraphase.

PY - 2020/9/1

Y1 - 2020/9/1

UR - http://www.scopus.com/inward/record.url?scp=85087288772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85087288772&partnerID=8YFLogxK

U2 - 10.1002/pbc.28504

DO - 10.1002/pbc.28504

M3 - Letter

C2 - 32573939

AN - SCOPUS:85087288772

VL - 67

JO - Medical and Pediatric Oncology

JF - Medical and Pediatric Oncology

SN - 1545-5009

IS - 9

M1 - e28504

ER -

Benign course of SARS-CoV-2 infection in a series of pediatric oncology patients

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this